10-Q: NovAccess Global Reports Net Income of $810,999 for Six Months Ended March 31, 2024, Amidst Financial Uncertainties

NovAccess Global reports a net income for the six months ended March 31, 2024, driven by gains on derivative liability and reduced expenses, but faces ongoing liquidity challenges and dependence on additional funding.

Summary

• NovAccess Global Inc. reported its financial results for the quarter and six months ended March 31, 2024.
• The company is a biopharmaceutical company focused on developing immunotherapies for brain tumor patients.
• For the three months ended March 31, 2024, the company's net loss was $492,594, compared to a net income of $409,523 for the same period in 2023.
• Selling, general, and administrative expenses decreased significantly to $196,280 from $1,013,952 in the prior year quarter.
• Research and development expenses slightly decreased to $36,275 from $41,036.
• For the six months ended March 31, 2024, the company reported a net income of $810,999, compared to a net loss of $2,221,883 for the same period in 2023.
• Selling, general, and administrative expenses decreased to $404,129 from $1,496,106.
• Research and development expenses increased to $85,972 from $76,000.
• The company had a working capital deficit of $6,853,896 as of March 31, 2024, compared to $7,798,484 as of September 30, 2023.
• The company's ability to continue as a going concern is dependent on additional cash infusions.
• NovAccess is pursuing a securities purchase agreement with Sumner Global LLC for $3.63 million in stock purchase and $7.05 million in loans, but the transaction is subject to contingencies and may not be completed.
• Subsequent to March 31, 2024, the company has issued additional shares of common stock upon conversion of debt and has entered into new loan agreements.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company reports a net income for the six-month period, it faces significant financial challenges, including a large working capital deficit and dependence on uncertain funding sources. The potential investment from Sumner Global is a positive factor, but the contingencies and delays associated with the transaction create uncertainty.

Positives

• The company achieved a net income of $810,999 for the six months ended March 31, 2024, a substantial turnaround from the previous year's loss.
• Significant reduction in selling, general, and administrative expenses indicates improved cost management.
• The decrease in the working capital deficit suggests a slight improvement in the company's short-term financial health.
• The potential investment from Sumner Global LLC could provide much-needed capital to fund operations and repay debt.
• The new intellectual property license from Cedars-Sinai Medical Center could enhance the company's immunotherapy platform and future prospects.

Negatives

• The company still faces a significant working capital deficit of $6,853,896 as of March 31, 2024.
• The company's auditor has raised substantial doubt about its ability to continue as a going concern.
• The Sumner Global LLC transaction is subject to contingencies and may not be completed, creating uncertainty about future funding.
• The company has a history of relying on debt financing, which could increase financial risk.
• The company has incurred net losses in previous periods, indicating a history of financial instability.

Risks

• The company's ability to continue as a going concern is highly dependent on securing additional funding.
• The Sumner Global LLC transaction is subject to contingencies and may not be completed.
• The company's reliance on debt financing could lead to increased financial risk and potential default.
• Delays in filing financial reports have previously resulted in loan defaults.
• The company's success is dependent on the successful development and commercialization of its biopharmaceutical products, which is subject to regulatory approval and market acceptance.

Future Outlook

The company plans to submit an IND application in 2024 if funding is available and expects to need at least $3.0 million through December 31, 2024, to finance ongoing operations and complete its IND application.

Management Comments

• Management believes the existing shareholders, prospective new investors and lenders will provide the additional cash needed to meet the Company's obligations as they become due and will allow the development of its business.
• Messrs. Irvin and Laird concluded that the Company's disclosure controls and procedures were effective as of March 31, 2024.

Industry Context

NovAccess Global is operating in the competitive biopharmaceutical industry, focusing on novel immunotherapies for brain tumor patients, a field with significant unmet medical needs and potential for high-value therapeutics.

Comparison to Industry Standards

• It is difficult to compare NovAccess to industry standards due to its early stage and lack of revenue.
• Companies like Celldex Therapeutics and Northwest Biotherapeutics are also developing immunotherapies for glioblastoma, but they are at different stages of development and have different financial profiles.
• NovAccess's reliance on debt financing and the uncertainty surrounding the Sumner Global transaction are atypical for companies in more advanced stages of clinical development.

Related Party Transactions

• During the six months ended March 31, 2024, the Company issued 217,500 shares to a related party for services provided amounting to $3,208 recorded at the fair value of shares on the respective grant dates.
• As of March 31, 2024, the Company owed TN3 $95,000 of the redemption price and was in default.
• On January 26, 2024, Jason Anderson loaned the Company a further $2,000 to address short-term cash needs.
• On December 21, 2023, our Chairman, John A. Cassarini loaned the Company $10,000 to address short-term cash need.
• Our Chief Financial Officer, Neil J. Laird loaned the Company $1,000.

Stakeholder Impact

• Shareholders face uncertainty due to the company's financial instability and dependence on additional funding.
• Employees' job security is contingent on the company's ability to secure funding and continue operations.
• Customers (potential patients) may benefit from the successful development and commercialization of the company's immunotherapies.
• Suppliers and creditors face the risk of non-payment if the company's financial situation does not improve.

Next Steps

• The company plans to submit an IND application to the FDA in 2024 if funding is available.
• The company is awaiting the completion of the securities purchase agreement with Sumner Global LLC.
• The company needs to secure additional funding to finance its ongoing operations and meet its financial obligations.

Key Dates

Keywords

biopharmaceutical, immunotherapy, brain tumor, glioblastoma, financial results, convertible notes, warrants, Sumner Global, liquidity, going concern